Provided by Tiger Trade Technology Pte. Ltd.

RenovoRx Inc

1.13
-0.0300-2.59%
Post-market: 1.130.00000.00%19:47 EDT
Volume:534.09K
Turnover:584.40K
Market Cap:53.44M
PE:-3.18
High:1.17
Open:1.15
Low:1.06
Close:1.16
52wk High:1.45
52wk Low:0.7006
Shares:47.29M
Float Shares:43.16M
Volume Ratio:0.79
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3554
EPS(LYR):-0.3958
ROE:-146.61%
ROA:-68.39%
PB:6.62
PE(LYR):-2.86

Loading ...

RenovoRx CEO Shaun Bagai Reports Acquisition of Common Shares

Reuters
·
Dec 22, 2025

RenovoRx CEO Shaun Bagai Reports Acquisition of Common Shares

Reuters
·
Dec 19, 2025

RenovoRx Chief Medical Officer Ramtin Agah Acquires Common Shares

Reuters
·
Dec 17, 2025

RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

GlobeNewswire
·
Dec 11, 2025

RenovoRx Chief Medical Officer Ramtin Agah Reports Acquisition of Common Shares

Reuters
·
Dec 08, 2025

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

GlobeNewswire
·
Dec 01, 2025

RenovoRx CMO Makes Bold Stock Purchase

TIPRANKS
·
Nov 25, 2025

RenovoRx Chief Medical Officer Ramtin Agah Acquires Common Shares

Reuters
·
Nov 25, 2025

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

GlobeNewswire
·
Nov 19, 2025

RenovoRx Showcases Cancer Therapy Advances and RenovoCath Commercialization in New Investor Presentation

Reuters
·
Nov 19, 2025

Strategic Expansion and Promising Clinical Results Justify Buy Rating for RenovoRx

TIPRANKS
·
Nov 18, 2025

RenovoRx’s Innovative Cancer Treatment and Promising Phase 3 Study Drive Buy Rating

TIPRANKS
·
Nov 16, 2025

RenovoRx Earnings Call: Positive Momentum and Strategic Growth

TIPRANKS
·
Nov 15, 2025

RenovoRx Enters Capital on Demand Sales Agreement

TIPRANKS
·
Nov 15, 2025

BRIEF-RenovoRx May Offer Securities For Up To $50 Million - SEC Filing

Reuters
·
Nov 15, 2025

RenovoRx Inc - May Offer Securities for up to $50 Mln - SEC Filing

THOMSON REUTERS
·
Nov 15, 2025

Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Forte Biosciences (FBRX)

TIPRANKS
·
Nov 15, 2025

RenovoRx price target lowered to $3 from $3.50 at Alliance Global

TIPRANKS
·
Nov 15, 2025

RenovoRx Expands Reach with RenovoCath Approval

TIPRANKS
·
Nov 14, 2025

Cancer drug developer RenovoRx's Q3 net loss widens

Reuters
·
Nov 14, 2025